MedTrace Logo

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

NCT06217146 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-06-27

No results posted yet for this study

Summary

This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of care (SoC), in reducing agitation and disruptive behaviors in subjects with dementia including probable AD.

Conditions

  • Agitation,Psychomotor
  • Disruptive Behavior
  • Dementia
  • Alzheimer Disease

Interventions

DRUG

Medical Cannabis

MediCane's medical cannabis oil

DRUG

Placebo Oil

Placebo Oil

Sponsors & Collaborators

  • M. H MediCane Ltd.

    lead INDUSTRY

Principal Investigators

  • Neta Rimmerman, PhD · Sponsor GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-12
Primary Completion
2024-03-10
Completion
2024-03-10

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06217146 on ClinicalTrials.gov